 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

JUPITER, Fla., Sept. 21, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- Dawson James Securities, Inc. ( Dawson ), a full-service investment bank focused on emerging growth companies, today announces...

Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference

For the last three days, A.I.dvisor has detected that ANVS's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...

Annovis Bio (ANVS, $10.6) Aroon Indicator entered a Downtrend on September 15, 2023.

This is a signal that ANVS's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...

Annovis Bio (ANVS, $10.6) RSI Indicator left the oversold zone on September 15, 2023

Annovis Bio (ANVS, $10.92) Aroon Indicator entered a Downtrend on September 14, 2023.

Annovis Bio (ANVS, $10.55) RSI Indicator left the oversold zone on September 13, 2023

Annovis Bio (ANVS, $10.55) Aroon Indicator entered a Downtrend on September 13, 2023.

Annovis Bio (ANVS, $11.15) Aroon Indicator entered a Downtrend on September 12, 2023.

Annovis Bio (ANVS, $11.55) Aroon Indicator entered a Downtrend on September 11, 2023.

Annovis Bio, Inc. (NYSE:ANVS  Get Free Report) shares were up 2.8% on Friday . The company traded as high as $11.44 and last traded at $11.23. Approximately 30,646 shares traded hands during...

Annovis Bio (NYSE:ANVS) Shares Up 2.8%

Annovis Bio (ANVS, $11.44) Aroon Indicator entered a Downtrend on September 08, 2023.

Annovis Bio, Inc. is a clinical stage drug platform company, which engages in the development of drugs which aims to treat neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s (PD). Its lead product candidate, Buntanetap, is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Its product pipeline also includes ANVS405 and ANVS301, which focus on the treatment of traumatic brain injury, stroke, and advanced AD. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Berwyn, PA.

Watchers	7,298
52-Wk Low	$9.26
52-Wk High	$23.89

Market Cap	$85.53M
Volume (M)	24,427.00
52-Wk High	$23.89
52-Wk Low	$9.26

ANVS Annovis Bio Inc

About

Feed

News

Sentiment

Earnings

Fundamentals